3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow compound 21: new trials by email Literature Review of compound 21 trials Research Report on compound 21
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF C21 - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Vicore Pharma AB | 52 | 2020-11-13 | 2025-05-23 |
| Safety and Efficacy of C21 in Subjects With COVID-19 C21, Placebo - COVID-19 | Phase 2 | Completed | Vicore Pharma AB | 206 | 2020-07-21 | 2021-06-23 |
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
COVID-19 (1) · Idiopathic Pulmonary Fibrosis (1) · Raynaud Disease (1) · Scleroderma, Systemic (1)
Vicore Pharma AB (3)
United Kingdom (3) · India (2) · Russia (1) · Ukraine (1)
Joanna Porter, MD (2) · Ariane Herrick, MD (1)
2019 (1)